Integrative genomic analysis identifies epigenetic marks that mediate genetic risk for epithelial ovarian cancer

BMC Medical Genomics

Volumn 7, Issue 1, 2014, Pages

  Koestler, Devin C ^a   Chalise, Prabhakar ^a   Cicek, Mine S ^b   Cunningham, Julie M ^b   Armasu, Sebastian ^b   Larson, Melissa C ^b   Chien, Jeremy ^a   Block, Matthew ^b   Kalli, Kimberly R ^b   Sellers, Thomas A ^c   Fridley, Brooke L ^a   Goode, Ellen L ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Blood based DNA methylation; Integrative genomics; Ovarian cancer

Indexed keywords

AGED; CASE-CONTROL STUDIES; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84893162063     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-7-8     Document Type: Article

References (76)

1. Cancer statistics, 2013. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2013 63 1 11 30 10.3322/caac.21166 23335087
2. Pharmacoeconomic considerations in treating ovarian cancer. Bodurka-Bevers D, Sun CC, Gershenson DM, Pharmacoeconomics 2000 17 2 133 150 10.2165/00019053-200017020-00003 10947337 (Pubitemid 30148811)
3. Projections of the cost of cancer care in the United States: 2010-2020. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML, J Natl Cancer Inst 2011 103 2 117 128 10.1093/jnci/djq495 21228314
4. Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K + channel. Cicek MS, Koestler DC, Fridley BL, Kalli KR, Armasu SM, Larson MC, Wang C, Winham SJ, Vierkant RA, Rider DN, et al. Hum Mol Genet 2013 22 15 3038 3047 10.1093/hmg/ddt160 23571109
5. Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles. Bauerschlag DO, Ammerpohl O, Brautigam K, Schem C, Lin Q, Weigel MT, Hilpert F, Arnold N, Maass N, Meinhold-Heerlein I, et al. Oncology 2011 80 1-2 12 20 21577013
6. DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. Watts GS, Futscher BW, Holtan N, Degeest K, Domann FE, Rose SL, BMC Med Genomics 2008 1 47 10.1186/1755-8794-1-47 18826610
7. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, et al. Nat Commun 2013 4 1628 23535649
8. Peripheral blood DNA methylation profiles are indicative of head and neck squamous cell carcinoma: an epigenome-wide association study. Langevin SM, Koestler DC, Christensen BC, Butler RA, Wiencke JK, Nelson HH, Houseman EA, Marsit CJ, Kelsey KT, Epigenetics 2012 7 3 291 299 10.4161/epi.7.3.19134 22430805
9. DNA methylation array analysis identifies profiles of blood-derived DNA methylation associated with bladder cancer. Marsit CJ, Koestler DC, Christensen BC, Karagas MR, Houseman EA, Kelsey KT, J Clin Oncol 2011 29 9 1133 1139 10.1200/JCO.2010.31.3577 21343564
10. Leukocyte DNA methylation signature differentiates pancreatic cancer patients from healthy controls. Pedersen KS, Bamlet WR, Oberg AL, de Andrade M, Matsumoto ME, Tang H, Thibodeau SN, Petersen GM, Wang L, PLoS One 2011 6 3 18223 10.1371/journal.pone.0018223 21455317
11. Methylation markers for small cell lung cancer in peripheral blood leukocyte DNA. Wang L, Aakre JA, Jiang R, Marks RS, Wu Y, Chen J, Thibodeau SN, Pankratz VS, Yang P, J Thorac Oncol 2010 5 6 778 785 10.1097/JTO. 0b013e3181d6e0b3 20421821
12. An epigenetic signature in peripheral blood predicts active ovarian cancer. Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Gayther SA, Apostolidou S, Jones A, Lechner M, Beck S, Jacobs IJ, et al. PLoS One 2009 4 12 8274 10.1371/journal.pone.0008274 20019873
13. DNA methylation arrays as surrogate measures of cell mixture distribution. Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, Wiencke JK, Kelsey KT, BMC Bioinforma 2012 13 1 86 10.1186/1471-2105-13-86
14. Peripheral blood immune cell methylation profiles are associated with nonhematopoietic cancers. Koestler DC, Marsit CJ, Christensen BC, Accomando W, Langevin SM, Houseman EA, Nelson HH, Karagas MR, Wiencke JK, Kelsey KT, Cancer Epidemiol Biomarkers Prev 2012 21 8 1293 1302 10.1158/1055-9965.EPI-12-0361 22714737
15. Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility. Reinius LE, Acevedo N, Joerink M, Pershagen G, Dahlen SE, Greco D, Soderhall C, Scheynius A, Kere J, PLoS One 2012 7 7 41361 10.1371/journal.pone.0041361 22848472
16. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Liu Y, Aryee MJ, Padyukov L, Fallin MD, Hesselberg E, Runarsson A, Reinius L, Acevedo N, Taub M, Ronninger M, et al. Nat Biotechnol 2013 31 2 142 147 10.1038/nbt.2487 23334450
17. Epigenomic alterations in localized and advanced prostate cancer. Lin PC, Giannopoulou EG, Park K, Mosquera JM, Sboner A, Tewari AK, Garraway LA, Beltran H, Rubin MA, Elemento O, Neoplasia 2013 15 4 373 383 23555183
18. A decade of exploring the cancer epigenome-biological and translational implications. Baylin SB, Jones PA, Nat Rev Cancer 2011 11 10 726 734 10.1038/nrc3130 21941284
19. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, et al. Nat Genet 2010 42 10 880 884 10.1038/ng.666 20852633
20. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, et al. Nat Genet 2010 42 10 874 879 10.1038/ng.668 20852632
21. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-Culver H, Chang-Claude J, Cramer DW, DiCioccio R, et al. Nat Genet 2009 41 9 996 1000 10.1038/ng.424 19648919
22. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley M, Fridley BL, Tyrer JP, Shen H, et al. Nat Genet 2013 45 4) 362 370 370e361-362 23535730
23. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, Edwards SL, Pickett HA, Shen HC, Smart CE, et al. Nat Genet 2013 45 4 371 384 384e371-372 10.1038/ng.2566 23535731
24. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, Lin HY, Chen YA, Tsai YY, Qu X, et al. Nat Commun 2013 4 1627 23535648
25. Genome-wide association study identifies a locus at 7p15.2 associated with endometriosis. Painter JN, Anderson CA, Nyholt DR, Macgregor S, Lin J, Lee SH, Lambert A, Zhao ZZ, Roseman F, Guo Q, et al. Nat Genet 2011 43 1 51 54 10.1038/ng.731 21151130
26. Programming of DNA methylation patterns. Cedar H, Bergman Y, Annu Rev Biochem 2012 81 97 117 10.1146/annurev-biochem-052610-091920 22404632
27. LIN28B Polymorphisms influence susceptibility to epithelial ovarian cancer. Permuth-Wey J, Kim D, Tsai YY, Lin HY, Chen YA, Barnholtz-Sloan J, Birrer MJ, Bloom G, Chanock SJ, Chen Z, et al. Cancer Res 2011 71 11 3896 3903 10.1158/0008-5472.CAN-10-4167 21482675
28. SNPnexus: a web database for functional annotation of newly discovered and public domain single nucleotide polymorphisms. Chelala C, Khan A, Lemoine NR, Bioinformatics 2009 25 5 655 661 10.1093/bioinformatics/btn653 19098027
29. SNPnexus: a web server for functional annotation of novel and publicly known genetic variants (2012 update). Dayem Ullah AZ, Lemoine NR, Chelala C, Nucleic Acids Res 2012 40 Web Server issue 65 W70 22544707
30. A practical guide for the functional annotation of genetic variations using SNPnexus. Dayem Ullah AZ, Lemoine NR, Chelala C, Brief Bioinform 2013 14 4 437 447 10.1093/bib/bbt004 23395730
31. Influence of genetic background and tissue types on global DNA methylation patterns. Yang HH, Hu N, Wang C, Ding T, Dunn BK, Goldstein AM, Taylor PR, Lee MP, PLoS One 2010 5 2 9355 10.1371/journal.pone.0009355 20186319
32. Batch effects and pathway analysis: two potential perils in cancer studies involving DNA methylation array analysis. Harper KN, Peters BA, Gamble MV, Cancer Epidemiol Biomarkers Prev 2013 22 6 1052 1060 10.1158/1055-9965.EPI- 13-0114 23629520
33. Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, Hou L, Lin SM, BMC Bioinforma 2010 11 587 10.1186/1471-2105-11-587
34. A statistical framework for Illumina DNA methylation arrays. Kuan PF, Wang S, Zhou X, Chu H, Bioinformatics 2010 26 22 2849 2855 10.1093/ bioinformatics/btq553 20880956
35. Adjusting batch effects in microarray expression data using empirical Bayes methods. Johnson WE, Li C, Rabinovic A, Biostatistics 2007 8 1 118 127 10.1093/biostatistics/kxj037 16632515 (Pubitemid 44906106)
36. Removing batch effects in analysis of expression microarray data: an evaluation of six batch adjustment methods. Chen C, Grennan K, Badner J, Zhang D, Gershon E, Jin L, Liu C, PLoS One 2011 6 2
37. Batch correction of microarray data substantially improves the identification of genes differentially expressed in rheumatoid arthritis and osteoarthritis. Kupfer P, Guthke R, Pohlers D, Huber R, Koczan D, Kinne RW, BMC Med Genomics 2012 5 23 10.1186/1755-8794-5-23 22682473
38. A comprehensive overview of infinium HumanMethylation450 data processing. Dedeurwaerder S, Defrance M, Bizet M, Calonne E, Bontempi G, Fuks F, Brief Bioinform 2013
39. ChAMP: 450k chip analysis methylation pipeline. Morris TJ, Butcher LM, Feber A, Teschendorff AE, Chakravarthy AR, Wojdacz TK, Beck S, Bioinformatics 2013
40. Review of processing and analysis methods for DNA methylation array data. Wilhelm-Benartzi CS, Koestler DC, Karagas MR, Flanagan JM, Christensen BC, Kelsey KT, Marsit CJ, Houseman EA, Brown R, Br J Cancer 2013 109 6 1394 1402 10.1038/bjc.2013.496 23982603
41. Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer. Bishara S, Griffin M, Cargill A, Bali A, Gore ME, Kaye SB, Shepherd JH, Van Trappen PO, Eur J Obstet Gynecol Reprod Biol 2008 138 1 71 75 10.1016/j.ejogrb.2007.05.012 17644243 (Pubitemid 351608106)
42. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K, Cancer Immunol Immunother 2009 58 1 15 23 10.1007/s00262-008-0516-3 18414853
43. Whole blood cell counts and leucocyte differentials in patients with benign or malignant ovarian tumours. den Ouden M, Ubachs JM, Stoot JE, van Wersch JW, Eur J Obstet Gynecol Reprod Biol 1997 72 1 73 77 10.1016/S0301- 2115(96)02662-0 9076425 (Pubitemid 27091287)
44. Blood-based profiles of DNA methylation predict the underlying distribution of cell types: a validation analysis. Koestler DC, Christensen B, Karagas MR, Marsit CJ, Langevin SM, Kelsey KT, Wiencke JK, Houseman EA, Epigenetics 2013 8 8
45. Disentangling molecular relationships with a causal inference test. Millstein J, Zhang B, Zhu J, Schadt EE, BMC Genet 2009 10 23 19473544
46. Statistical significance for genomewide studies. Storey JD, Tibshirani R, Proc Natl Acad Sci USA 2003 100 16 9440 9445 10.1073/pnas.1530509100 12883005 (Pubitemid 37033947)
47. DNA methylation profiles in monozygotic and dizygotic twins. Kaminsky ZA, Tang T, Wang SC, Ptak C, Oh GH, Wong AH, Feldcamp LA, Virtanen C, Halfvarson J, Tysk C, et al. Nat Genet 2009 41 2 240 245 10.1038/ng.286 19151718
48. Mapping complex disease traits with global gene expression. Cookson W, Liang L, Abecasis G, Moffatt M, Lathrop M, Nat Rev Genet 2009 10 3 184 194 10.1038/nrg2537 19223927
49. The genetics of regulatory variation in the human genome. Stranger BE, Dermitzakis ET, Hum Genomics 2005 2 2 126 131 10.1186/1479-7364-2-2-126 16004727
50. The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. Nica AC, Parts L, Glass D, Nisbet J, Barrett A, Sekowska M, Travers M, Potter S, Grundberg E, Small K, et al. PLoS Genet 2011 7 2 1002003 10.1371/journal.pgen.1002003 21304890
51. DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Bell JT, Pai AA, Pickrell JK, Gaffney DJ, Pique-Regi R, Degner JF, Gilad Y, Pritchard JK, Genome Biol 2011 12 1 10 10.1186/gb-2011-12-1-r10 21251332
52. Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. Gibbs JR, van der Brug MP, Hernandez DG, Traynor BJ, Nalls MA, Lai SL, Arepalli S, Dillman A, Rafferty IP, Troncoso J, et al. PLoS Genet 2010 6 5 1000952 10.1371/journal.pgen.1000952 20485568
53. Genetic control of individual differences in gene-specific methylation in human brain. Zhang D, Cheng L, Badner JA, Chen C, Chen Q, Luo W, Craig DW, Redman M, Gershon ES, Liu C, Am J Hum Genet 2010 86 3 411 419 10.1016/j.ajhg.2010.02.005 20215007
54. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, et al. Nature 2008 455 7215 967 970 10.1038/nature07398 18923523
55. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Webb TR, Slavish J, George RE, Look AT, Xue L, Jiang Q, Cui X, Rentrop WB, Morris SW, Expert Rev Anticancer Ther 2009 9 3 331 356 10.1586/14737140.9.3.331 19275511
56. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, Ho KK, Au JS, Chung LP, Pik Wong M, Cancer 2009 115 8 1723 1733 10.1002/cncr.24181 19170230
57. IL-2R common gamma-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK. Zhang Q, Wang HY, Liu X, Bhutani G, Kantekure K, Wasik M, Proc Natl Acad Sci USA 2011 108 29 11977 82 10.1073/pnas.1100319108 21715655
58. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH, Nelson BH, PLoS One 2009 4 7 6412 10.1371/journal.pone.0006412 19641607
59. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Kostova N, Zlateva S, Ugrinova I, Pasheva E, Mol Cell Biochem 2010 337 1-2 251 258 19876719
60. Overexpression of high mobility group (HMG) B1 and B2 proteins directly correlates with the progression of squamous cell carcinoma in skin. Sharma A, Ray R, Rajeswari MR, Cancer Invest 2008 26 8 843 851 10.1080/07357900801954210 18798064
61. Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Gnanasekar M, Thirugnanam S, Ramaswamy K, Int J Oncol 2009 34 2 425 431 19148477
62. Effect of HMGB1 silencing on cell proliferation, invasion and apoptosis of MGC-803 gastric cancer cells. Song B, Song WG, Li ZJ, Xu ZF, Wang XW, Wang CX, Liu J, Cell Biochem Funct 2011
63. Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. Yao X, Zhao G, Yang H, Hong X, Bie L, Liu G, J Cancer Res Clin Oncol 2010 136 5 677 684 10.1007/s00432-009-0706-1 19898867
64. Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Jiao Y, Wang HC, Fan SJ, Acta Pharmacol Sin 2007 28 12 1957 1967 10.1111/j.1745-7254.2007.00669.x 18031610 (Pubitemid 350198338)
65. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM, Proc Natl Acad Sci USA 2004 101 25 9309 9314 10.1073/pnas. 0401994101 15184677 (Pubitemid 38812872)
66. Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma. Wang W, Jiang H, Zhu H, Zhang H, Gong J, Zhang L, Ding Q, Oncol Lett 2013 5 3 884 888 23426143
67. SET complex in serous epithelial ovarian cancer. Ouellet V, Le Page C, Guyot MC, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM, Int J Cancer 2006 119 9 2119 2126 10.1002/ijc.22054 16823850 (Pubitemid 44423670)
68. Circulating tumor cells: approaches to isolation and characterization. Yu M, Stott S, Toner M, Maheswaran S, Haber DA, J Cell Biol 2011 192 3 373 382 10.1083/jcb.201010021 21300848
69. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Bianchi ME, Manfredi AA, Immunol Rev 2007 220 35 46 10.1111/j.1600-065X.2007.00574.x 17979838 (Pubitemid 350045574)
70. HMGB1: a signal of necrosis. Raucci A, Palumbo R, Bianchi ME, Autoimmunity 2007 40 4 285 289 10.1080/08916930701356978 17516211 (Pubitemid 46845522)
71. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Scaffidi P, Misteli T, Bianchi ME, Nature 2002 418 6894 191 195 10.1038/nature00858 12110890 (Pubitemid 34773774)
72. EVI2B, ATP2A2, S100B, TM4SF3, and OLFM4 as potential prognostic markers for postoperative Taiwanese colorectal cancer patients. Huang MY, Wang HM, Tok TS, Chang HJ, Chang MS, Cheng TL, Wang JY, Lin SR, DNA Cell Biol 2012 31 4 625 635 10.1089/dna.2011.1365 22047082
73. TAF15 is important for cellular proliferation and regulates the expression of a subset of cell cycle genes through miRNAs. Ballarino M, Jobert L, Dembele D, de la Grange P, Auboeuf D, Tora L, Oncogene 2012 32 39 4646 4655 23128393
74. Factors underlying variable DNA methylation in a human community cohort. Lam LL, Emberly E, Fraser HB, Neumann SM, Chen E, Miller GE, Kobor MS, Proc Natl Acad Sci USA 2012 109 Suppl 2 17253 17260 23045638
75. Temporal stability of epigenetic markers: sequence characteristics and predictors of short-term DNA methylation variations. Byun HM, Nordio F, Coull BA, Tarantini L, Hou L, Bonzini M, Apostoli P, Bertazzi PA, Baccarelli A, PLoS One 2012 7 6 39220 10.1371/journal.pone.0039220 22745719
76. Epigenome-wide association study of breast cancer using prospectively collected sister study samples. Xu Z, Bolick SC, DeRoo LA, Weinberg CR, Sandler DP, Taylor JA, J Natl Cancer Inst 2013 105 10 694 700 10.1093/jnci/djt045 23578854